1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24357
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBozionelou, V.en
dc.contributor.authorVamvakas, L.en
dc.contributor.authorPappas, P.en
dc.contributor.authorAgelaki, S.en
dc.contributor.authorAndroulakis, N.en
dc.contributor.authorKalykaki, A.en
dc.contributor.authorNikolaidou, M.en
dc.contributor.authorKentepozidis, N.en
dc.contributor.authorGiassas, S.en
dc.contributor.authorMarselos, M.en
dc.contributor.authorGeorgoulias, V.en
dc.contributor.authorMavroudis, D.en
dc.date.accessioned2015-11-24T19:40:27Z-
dc.date.available2015-11-24T19:40:27Z-
dc.identifier.issn0007-0920-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24357-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverseen
dc.subjecteffects/pharmacokineticsen
dc.subjectDeoxycytidine/administration & dosage/*analogs & derivatives/pharmacokineticsen
dc.subjectDoxorubicin/administration & dosage/*analogs & derivatives/pharmacologyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMaximum Tolerated Doseen
dc.subjectMiddle Ageden
dc.subjectNeoplasms/*drug therapyen
dc.subjectNeutropenia/chemically induceden
dc.subjectPaclitaxel/*administration & dosage/pharmacokineticsen
dc.subjectPolyethylene Glycols/*administration & dosage/pharmacologyen
dc.subjectSurvival Rateen
dc.titleA dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumoursen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1038/sj.bjc.6603832-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17551496-
heal.identifier.secondaryhttp://www.nature.com/bjc/journal/v97/n1/pdf/6603832a.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2007-
heal.abstractTo determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of pegylated liposomal doxorubicin (PLD), paclitaxel (PCX) and gemcitabine (GEM) combination administered biweekly in patients with advanced solid tumours. Twenty-two patients with advanced-stage solid tumours were treated with escalated doses of PLD on day 1 and PCX plus GEM on day 2 (starting doses: 10, 100 and 800 mg m(-2), respectively) every 2 weeks. DLTs and pharmacokinetic (PK) parameters of all drugs were determined during the first cycle of treatment. All but six (73%) patients had previously received at least one chemotherapy regimen. The DLT dose level was reached at PLD 12 mg m(-2), PCX 110 mg m(-2) and GEM 1000 mg m(-2) with neutropaenia being the dose-limiting event. Of the 86 chemotherapy cycles delivered, grade 3 and 4 neutropaenia occurred in 20% with no cases of febrile neutropaenia. Non-haematological toxicities were mild. The recommended MTDs are PLD 12 mg m(-2), PCX 100 mg m(-2) and GEM 1000 mg m(-2) administered every 2 weeks. The PK data revealed no obvious drug interactions. Biweekly administration of PLD, PCX and GEM is a well-tolerated chemotherapy regimen, which merits further evaluation in various types of solid tumours.en
heal.journalNameBr J Canceren
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Bozionelou-2007-A dose escalation an.pdf112.68 kBAdobe PDFView/Open
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons